A new instrument is being developed by researchers at the University of Calgary in Canada to enable the quick and precise measurement of proteins and other small molecules that can indicate brain injuries, such as concussion.

Two hours after a suspected injury, the Diagnostic and measurement devices pipeline products market will have electrodes that can identify key biomarkers in blood samples from patients. The test will only necessitate a small amount of blood.

"We want a more exact and precise method for distinguishing blackout, as well as a method for anticipating recuperation."
The electrochemical immunosensor made of polyethylenimine makes use of microfluidic technology to automate the sensing procedure.
It is said to be at least 100 times more sensitive than other biomarker approaches for brain injury that are currently being tested.

The researchers anticipate that the tool will address the unmet diagnostic needs of rural health care facilities, war-affected populations, clinics with limited resources, and those without emergency vehicles.

In addition, the device is said to have the capability of providing primary interventions, injury assessment, and prognosis in hospitals, as well as priority-based injury diagnosis in clinics.

Chantel Debert, a clinical assistant professor at the Cumming School of Medicine at the University of Calgary, stated: It would assist in accurately diagnosing and determining outcomes, ensuring that patients receive prompt injury assessments, and monitoring their complete recovery.

"At present blackout is analyzed in view of clinical judgment, which is dependent upon understanding. We require a method that can both predict recovery and detect concussions with greater precision.